KPTI

XPOVIO (selinexor) is made by Karyopharm Therapeutics (Nasdaq: KPTI) "A couple of patients went into complete remission. For a small molecule to be able to eradicate the tumor so completely is mind-boggling and quite impressive. Moreover this is an orally administered drug that makes it very easy for patients to take it at home. Moreover, the side-effect profile is also impressive. It has no organ toxicity, no cardiac toxicity, no liver toxicity, renal toxicity, no neuropathy..." Sundar Jagannath, MD, a professor of medicine, hematology, and medical oncology at The Tisch Cancer Institute, Mount Sinai Hospital

KARYOPHARM THERAPEUTICS (KPTI) RESEARCH NOTES

  • Commercial-stage, global pharmaceutical company with multiple FDA approvals for various oncology indications and multiple additional drug candidates in clinical development.

  • Industry leader in targeting nuclear export dysregulation as a mechanism to treat cancer.

  • On top of Barclay's list as potential acquisition target at about $60/share.

  • Several analysts predict blockbuster sales.

  • Over 80% institutional interest

  • Analysts are very optimistic. HC Wainwright & Co. reiterated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $26.00 (Aug 6 2021), Morgan Stanley with a $29 target, and so on. Future should be very bright for this company.

  • Numerous upcoming catalysts


Latest Corporate Presentation (August 5, 2021) https://filecache.investorroom.com/mr5ir_karyopharm/268/KPTI-2Q21-Earnings-Slides%208.11.pdf


LATEST ANALYST SENTIMENTS:

  • HC Wainwright: Buy. Price Target: $26

  • Baird: Outperform. Price Target: $17


UPCOMING CATALYSTS for KPTI in remainder of 2021

  • Continue to enhance commercial capabilities; continue to increase U.S. XPOVIO sales


  • Initiation of Phase 3 study evaluating XPOVIO + pomalidomide in patients with multiple myeloma


  • SIENDO Phase 3 top-line data announced


  • Initiation of key late-stage clinical studies in MDS, NSCLC, myelofibrosis, and CRC5.


  • Additional combination data in hematologic and solid tumor malignancies with XPOVIO and other standard of care anti-cancer drugs to be presented at ESMO 2021 (September) and other medical meetings


  • Host investor day to outline strategic imperative and pipeline priorities

  • Surprise buyout announcement very possible.



MAY THE BETTING WAR FOR BUYING KARYOPHARM BEGIN. POTENTIAL BIDDERS:


  • Pfizer - PFE

  • Gilead - GILD

  • Merck - MRK

  • Vertex - VRTX

  • Takeda - TAK

  • Bristol Myers Squibb - BMY


PATIENT SPEAKS


A patient who significantly benefited from Selinexor, objected to the bashing of Selinexor by these funny doctors.


I am a 14 1/2 year Multiple Myeloma warrior. I have had two stem cell transplants and two Car T cell transplants. Have also had 26 chemotherapy drugs.


15 years ago this month I was told I had 3 years to live with Multiple Myeloma. Bam! Still here, bitches! #MultipleMyeloma #myelomawarrior #selinexor #karyopharm


Not sure why he would deny patients the opportunity to try Selinexor. I have been on it since September of 2019. We manage the side effects and I am alive because of this drug. All patients should deserve a chance at more special moments with their loved ones. #selinexor


Someone wrote:

This patient is not just a warrior but a Bodhisattva/SeniorMasterChief/! I will never understand why the FDA allows many of these extremely conflicted “experts” to speak out at advisory panel meetings. They are corrupt beyond what I can stomach.

25 Nov 2021 - Dr. Joshua Richter, MD: A second generation selinexor.

A second generation selinexor. Very interesting drug in myeloma. Unclear what it’s future is in this space, but one day would love to have this drug in our regular arsenal.

https://twitter.com/joshuarichtermd/status/1463700651888807941?s=21

22 NOV 2021 - MUST LISTEN CONFERENCE CALL AT JEFFERY'S

https://wsw.com/webcast/jeff201/kpti/1854288